Elagolix

Contraindicated

Elagolix Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details Elagolix Cyclosporine Injection Atopica Increased elagolix exposure and an increased risk of elagolix-related adverse reactions Details Elagolix Cyclosporine Ophthalmic Cequa Increased elagolix exposure and an increased risk of elagolix-related adverse reactions Details Elagolix Darolutamide Nubeqa Increased elagolix exposure and an increased risk of elagolix-related adverse reactions Details Elagolix Enasidenib Idhifa Increased elagolix exposure and an increased risk of elagolix-related adverse reactions Details Elagolix Fostemsavir Rukobia Increased elagolix exposure and an increased risk of elagolix-related adverse reactions Details Elagolix Gemfibrozil Lopid Increased elagolix exposure and an increased risk of elagolix-related adverse reactions Details

Major

Elagolix Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Elagolix Abametapir Explained Increased exposure of CYP3A4 substrate Details Elagolix Omeprazole Gastrobim Explained Increased omeprazole exposure Details Elagolix Buprenorphine Belbuca Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Elagolix Relugolix Orgovyx Explained Increased relugolix exposure Details Elagolix Atogepant Qulipta Reduced atogepant exposure Details Elagolix Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Elagolix Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Elagolix Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Elagolix Amlodipine Amvaz® Reduced amLODIPine exposure Details Elagolix Bedaquiline Sirturo Reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Elagolix Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Elagolix Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Elagolix Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Elagolix Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Elagolix Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Elagolix Digoxin Cardoxin® Increased digoxin exposure Details Elagolix Doravirine Pifeltro Reduced doravirine exposure and reduced efficacy of doravirine Details Elagolix Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Elagolix Entrectinib Rozlytrek Reduced entrectinib exposure and reduced efficacy of entrectinib Details Elagolix Erdafitinib Balversa Reduced erdafitinib exposure Details Elagolix Estradiol Delestrogen Increased estrogen exposure, reduced progestin efficacy, and reduced elagolix efficacy Details Elagolix Estradiol Topical Divigel Increased estrogen exposure, reduced progestin efficacy, and reduced elagolix efficacy Details Elagolix Estradiol Transdermal Patch Alora® Increased estrogen exposure, reduced progestin efficacy, and reduced elagolix efficacy Details Elagolix Fentanyl Transdermal Patch Duragesic® Reduced exposure of fentaNYL, reduced efficacy of fentaNYL and/or onset of opioid withdrawal symptoms Details Elagolix Finerenone Kerendia Reduced finerenone exposure and reduced efficacy of finerenone Details Elagolix Ketoconazole Topical Extina® Foam Increased elagolix exposure Details Elagolix Lefamulin Xenleta Altered (increased or reduced) lefamulin exposure, an increased risk of lefamulin-related adverse reactions and reduced efficacy o... Details Elagolix Leflunomide Arava Increased exposure of OATP1B1/1B3 substrate Details Elagolix Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir, incr... Details Elagolix Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir, incr... Details Elagolix Leniolisib Joenja Increased elagolix exposure, reduced leniolisib exposure and reduced efficacy of leniolisib Details Elagolix Letermovir Injection Prevymis Increased CYP3A substrate exposure Details